Lilly is currently delivering on one of the industry's best mid-stage pipelines. Some of the highlights on the list include a gamma secretase inhibitor and antibody for the treatment of Alzheimer's disease, mGlu2/3 for the treatment of schizophrenia, Hypnion for sleep deprivation, and Neri IV for the treatment of depression. Other important medicines in development include treatments for diabetes, osteoporosis, rheumatoid arthritis, and a number of treatments for cancer.

New Drug Application Submitted For Review to the U.S. Food and Drug Administration

  • Duloxetine - for chronic pain
  • Exenatide - for monotherapy treatment of type 2 diabetes
  • Olanzapine - for adolescent schizophrenia and bipolar disorder
  • Olanzapine LAI - long-acting injection delivery for schizophrenia
  • Olanzapine-Fluoxetine - for treatment-resistant depression
  • Prasugrel - for prevention/reduction of atherothrombotic events in patients with acute coronary syndromes who undergo percutaneous coronary intervention (PCI) (in collaboration with Daiichi Sankyo Company, Ltd.)
  • Ruboxistaurin mesylate - for diabetic retinopathy
  • Teriparatide (rDNA origin) - for glucocorticoid-induced osteoporosis

Select Drug Candidates in Late-Stage Investigation

  • A-beta lowering - for Alzheimer’s disease (Gamma secretase inhibitor)
  • Arzoxifene - for the prevention and treatment of osteoporosis and breast cancer risk reduction
  • Dirucotide - for secondary progressive multiple sclerosis (SPMS) (in collaboration with BioMS Medical Corp.)
  • Enzastaurin - for poor prognosis patients with diffuse large B-cell lymphoma
  • Exenatide - for once-weekly dosing
  • Prasugrel - for prevention/reduction of atherothrombotic events in patients with acute coronary syndromes who are medically managed (in collaboration with Daiichi Sankyo Company, Ltd.)
  • Teplizumab - for type 1 diabetes (in collaboration with MacroGenics)

Select Drug Candidates in Mid-Stage Investigation (Phase I or Phase II)

  • A-beta antibody - for Alzheimer's disease
  • Anti-CD20 (AME133v) - for non-Hodgkins lymphoma (NHL)
  • ASAP - for solid tumors
  • Gemcitabine prodrug - for solid tumors
  • GLP-1 analog - for type 2 diabetes
  • Glucokinase activator - for type 2 diabetes (in collaboration with OSI Pharmaceuticals, Inc.)
  • LP10152 - for diabetes
  • LY2624803 - for insomnia
  • mGlu2/3 prodrug - for schizophrenia
  • NERI IV - for depression (Phase II); for ADHD (Phase I)
  • OpRa II - for alcohol dependence
  • Survivin ASO - for solid tumors

Information is current as of October 3, 2008. The search for new drugs is risky and uncertain, and there are no guarantees. Remaining scientific and regulatory hurdles may cause pipeline compounds to be delayed or even to fail to reach the market.